Home > Journals > Indian Journal of Genetics and Molecular Research

Indian Journal of Genetics and Molecular Research

Submit your article Read this Journals View all journals
Full Text (PDF)
Original Article

Regulatory Role of PPAR Agonist Pioglitazone in Osteoclastogenesis of Type2 Diabetic Postmenopausal Women

Samuel Shila, Scientific officer & Head, No.7, 3rd street, Judge colony, Tambaram Sanatorium, Chennai, 600047. , Khashim Zenith* , Vashum Yaongamphi* , Loganathan Tholcopiyan* , Samuel Shila**

Author Information

Licence:



Indian Journal of Genetics and Molecular Research 6(1):p 7-14, January - June 2017. | DOI: http://dx.doi.org/10.21088/ijgmr.2319.4782.6117.1

How Cite This Article:

Timeline

Received : N/A         Accepted : N/A          Published : N/A

Abstract

Pioglitazone, a class of thiazolidinedione (TZDs) is a ligands for peroxisome poliferator activated receptor gamma (PPAR). Activation of PPAR receptors negatively regulates bone haemostasis. The present study focuses mainly into two categories firstly generation of functional osteoclasts and second, to study the impact of pioglitazone and estrogen on bone health. whole blood were taken from diabetic and non diabetic postmenopausal women to measures the baseline parameters and for isolation of peripheral blood mononuclear cells (PBMC) and cultured in osteoclasts medium for 14 days into following five groups: PBMCs from non diabetic postmenopausal women, PBMCs from type 2 diabetic postmenopausal women, PBMCs from type 2 diabetic Postmenopausal + Pioglitazone, PBMCs from type 2 diabetic Postmenopausal + Pioglitazone + 17 beta estradiol and PBMCs from type 2 diabetic Postmenopausal + 17 beta estradiol. Mrna expression was analysed for Cathepsin K. Increase in the numbers of TRAP positive multinucleated cells was observed in pioglitazone treated cells of type2 diabetic postmenopausal women (88.12 ± 12.25, p<0.001) as compared to type2 diabetic (46.46 ± 11.54), non diabetic (40.85 ± 9.45) co treated (68.44 ± 15.12, p<0.01) and estrogen treated type 2 diabetic postmenopausal women (39.12 ± 9.11, p <0.0001). In addition the expression ratio of Cathepsin K mRNA was significantly greater in pioglitazone treated type2 diabetic postmenopausal women as compared to other groups (p<0.05). We found that, PPARã agonist pioglitazone induced formation of TRAP positive multinucleated cells and upregulates the expression of bone resorption gene Cathepsin K leading to osteoclastogenesis in type2 diabetic postmenopausal women.

 

References

No records found.


About this article

Cite this article

Licence:



Received Accepted Published
N/A N/A N/A
DOI: http://dx.doi.org/10.21088/ijgmr.2319.4782.6117.1

Keywords

Pioglitazone; Osteoclast; Type2 Diabetes Mellitus. 

Article Level Metrics

Last Updated

Monday 22 June 2026, 00:00:55 (IST)

941

Accesses

2
274
00

Citations


NA
NA
NA

Download citation


Article Keywords

Keyword Highlighting

Highlight selected keywords in the article text.


Timeline

Received N/A
Accepted N/A
Published N/A

licence




Access this article

Reprint Order Form
Buy this Article
Institutional Subscriptions

Share